Development of Neisseria gonorrhoeae in vitro susceptibility test methods for cefixime including quality control guidelines.
Cefixime was tested in a multilaboratory study to establish susceptibility testing interpretive criteria and quality control (QC) guidelines for Neisseria gonorrhoeae. Interpretive criteria were established by using triplicate testing of 102 representative gonococcal strains. Only a susceptible category was proposed for cefixime (greater than or equal to 31 mm and less than or equal to 0.25 micrograms/ml) because of very rare, resistant isolates. QC ranges [N. gonorrhoeae American Type Culture Collection (ATCC) 49226] were established using multiple GC agar lots, three disk lots, and a number of test replicates consistent with the National Committee for Clinical Laboratory Standards (NCCLS) M23-T guidelines. Cefixime was stable in GC agar medium for at least 21 days when stored at 2 degrees-5 degrees C. Oral third-generation cephalosporins, such as cefixime, appear to represent potentially useful clinical alternatives to parenteral drugs of the same class for single-dose therapy of gonorrhea.
Jones
R N
RN
University of Iowa Hospitals and Clinics, College of Medicine, Iowa City.
Gerlach
E H
EH
Koontz
F P
FP
Murray
P R
PR
Pfaller
M A
MA
Washington
J A
JA
Erwin
M E
ME
Knapp
C C
CC
D020682:Cefixime; D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000494:pharmacology; D002443:Ceftriaxone / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D004355:Drug Stability; D008826:Microbial Sensitivity Tests / Q000592:standards*; D009344:Neisseria gonorrhoeae / Q000187:drug effects*; D011786:Quality Control; D012044:Regression Analysis
D002443:Ceftriaxone; D020682:Cefixime; D002439:Cefotaxime